Latham & Watkins Advises Character Biosciences in US$93 Million Series B Financing Round

Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, has announced an oversubscribed US$93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases, starting with age-related macular degeneration (AMD). The funding was co-led by new investors aMoon and Luma Group, with additional participation from Bausch + Lomb and Jefferson Life Sciences, alongside existing investors Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures.

Latham & Watkins LLP represents Character Biosciences in the transaction with a corporate deal team led by Bay Area partners Benjamin Potter and Heather Deixler, with associates Shan Shan and Tyler Israel.